Thermo Fisher Scientific Inc.
TMONYSE
$667.55
Last price · USD
- Market cap
- $251.7B
- P/E
- 37.6x
- EV / EBITDA
- 24.5x
- P/S
- 5.6x
- FCF yield
- 2.5%
- Div. yield
- 0.25%
Multiples use last price and FY2025 annual figures. Market cap estimated from diluted shares.
Revenue
$44.56B
+3.9%
4Y CAGR +3.2%
Gross profit
$18.24B
+2.9%
4Y CAGR -1.8%
Operating income
$8.11B
+5.8%
4Y CAGR -5.8%
Net income
$6.74B
+6.3%
4Y CAGR -3.4%
EPS (diluted)
$17.74
+7.3%
4Y CAGR -2.3%
Free cash flow
$6.29B
-13.4%
4Y CAGR -2.7%
Revenue & net income
Fiscal 2021–2025 · USD
RevenueNet income
Valuation
At $667.55 · FY2025 fundamentals
- Market cap
- $251.7B
- Enterprise value
- $281.2B
- P/E
- 37.6x
- P/S
- 5.6x
- P/B
- 4.7x
- EV / EBITDA
- 24.5x
- EV / Sales
- 6.3x
- Earnings yield
- 2.7%
- FCF yield
- 2.5%
- Shareholder yield
- 1.4%
Profitability
Margins as a share of revenue
| Metric | Latest | 4Y ago | Trend |
|---|---|---|---|
| Gross margin | 40.9%-9.1pp | 50.1% | |
| Operating margin | 18.2%-8.1pp | 26.3% | |
| EBITDA margin | 25.7%-4.8pp | 30.5% | |
| Net margin | 15.1%-4.6pp | 19.7% | |
| FCF margin | 14.1%-3.8pp | 17.9% |
Returns & financial health
FY2025 with 4-year trend
| Metric | Latest | 4Y ago | Trend |
|---|---|---|---|
| Return on equity | 12.6% | 18.9% | |
| Return on invested capital | 9.0% | 12.4% | |
| Return on assets | 6.1% | 8.1% | |
| Debt / equity | 0.74x | 0.89x | |
| Net debt / EBITDA | 2.58x | 2.66x | |
| Current ratio | 1.89x | 1.50x |
Cash & equivalents
$9.85B
Total debt
$39.38B
Capital allocation
How TMO used its cash in FY2025
- Operating cash flow
- $7.82B
- Capital expenditure
- $1.52B
- Dividends paid
- $636M
- Share repurchases
- $3.00B
- Stock-based compensation
- $310M
- Diluted shares
- 377.0M
- Share count change (4Y)
- -5.0%
Analyst estimates
Consensus for upcoming fiscal years
| Fiscal year | Revenue | Growth | EPS | Growth |
|---|---|---|---|---|
| FY2025 actual | $44.56B | $17.74 | ||
| FY2026E16 analysts | $47.98B | +7.7% | $25.23 | +42.2% |
| FY2027E16 analysts | $50.52B | +5.3% | $27.64 | +9.5% |
| FY2028E6 analysts | $53.72B | +6.3% | $30.45 | +10.2% |
About Thermo Fisher Scientific Inc.
Healthcare · Medical - Diagnostics & Research
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets.
thermofisher.com- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Marc N. Casper
- Employees
- 125,000
- Headquarters
- Waltham, MA, US
- IPO date
- 1980-03-17
Thermo Fisher Scientific Inc. (TMO) — frequently asked questions
Answered from the company's SEC filings
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services.
Explore the full income statement, balance sheet and cash flow statement. Not investment advice.